WO2008133349A1 - Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif - Google Patents

Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif Download PDF

Info

Publication number
WO2008133349A1
WO2008133349A1 PCT/JP2008/058322 JP2008058322W WO2008133349A1 WO 2008133349 A1 WO2008133349 A1 WO 2008133349A1 JP 2008058322 W JP2008058322 W JP 2008058322W WO 2008133349 A1 WO2008133349 A1 WO 2008133349A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver
peptide
natriuretic peptide
cnp
anp
Prior art date
Application number
PCT/JP2008/058322
Other languages
English (en)
Japanese (ja)
Inventor
Isao Sakaida
Shuji Terai
Naoki Yamamoto
Original Assignee
National University Corporation, Yamaguchi University
Asubio Pharma Co., Ltd.
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation, Yamaguchi University, Asubio Pharma Co., Ltd., Daiichi Sankyo Company, Limited filed Critical National University Corporation, Yamaguchi University
Publication of WO2008133349A1 publication Critical patent/WO2008133349A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition for use in the prevention or treatment of cirrhosis or precancerous lesions comprising sodium diuretic peptide as an active ingredient.
  • Fibrosis in the liver is caused by chronic liver damage caused by various causes such as viral hepatitis and alcoholic hepatitis.
  • chronic liver disease for example, in the progression from viral hepatitis to cirrhosis.
  • Liver fibrosis plays an important role.
  • removing the cause of liver damage is the first treatment to prevent liver fibrosis, and therefore the development of treatments such as drugs that suppress effective fibrosis is the current treatment in liver disease. Is an extremely important research topic.
  • Liver fibrosis is a response to hepatocyte necrosis and damage, and it involves a complex number of factors. For example, it may be caused by liver inflammation or poisoning, changes in liver blood flow, or infections caused by liver viruses or bacteria. In addition, various storage abnormalities in hepatocytes are often associated with fibrosis. In addition, chemical substances such as alcohol and methotrexate, drugs, and circulatory disturbance to the liver such as chronic heart failure also cause liver fibrosis. The liver is not only composed of liver parenchymal cells that are responsible for liver function, but 40% of the total number of cells constituting the liver is non-parenchymal cells, and non-parenchymal cells are approximately 48% sinusoidal.
  • Hepatic stellate cells are derived from fibroblasts and belong to the myofibroblast family. Liver myofibroblasts are differentiated from undifferentiated mesenchymal cells, and in the organogenesis stage, they produce collagen to form a matrix that has ⁇ -actin in the cytoskeleton. Changes to inactive hepatic stellate cells. Hepatic stellate cells usually have lipid droplets containing vitamin ⁇ in the cytoplasm, and are located in the sinusoidal cavity in the liver between hepatocytes and sinusoidal endothelial cells to support the construction of sinusoids.
  • ECM extracellular matrix
  • PDGF platelet-derived growth factor
  • liver fibrosis is a condition in which ECM has accumulated excessively as a result of wound healing mechanisms for tissue injury in the liver.
  • ECM such as collagen in a living body maintains a certain balance while repeating production and degradation, but under pathological conditions, the balance is lost and fibrosis occurs.
  • Liver fibrosis occurs mainly due to inflammation caused by hepatitis virus and alcohol, and becomes prominent especially when inflammation becomes chronic.
  • hepatic stellate cells are activated by cytokines produced by Kupffer cells and liver macrophages and transformed into activated cells to produce a large amount of ECM such as collagen-fibronectin. It also plays a central role in liver fibrosis by producing matrix-degrading enzyme (MMP), its inhibitory factor (TIMP), TGF_3, PDGF and other growth factors, and HGF.
  • MMP matrix-degrading enzyme
  • TGF_3, PDGF and other growth factors and HGF.
  • Activated hepatic stellate cells have enhanced contractility and are involved in the regulation of hepatic blood flow, and the expression of various site force-in receptors increases, making them highly sensitive to site force-in.
  • TGF-; 3 is a site force-in that most promotes liver fibrosis and promotes collagen production.
  • TNF- ⁇ and IFN-a suppress collagen production.
  • TGF-jS increases during hepatic fibrosis, activates hepatic stellate cells by the action of paracrine and autocrine, promotes ECM production, enhances TIMP production in hepatic stellate cells, and degrades ECM. Fibrosis progresses in order to reduce it relatively.
  • PDGF is also considered to be the most important cytokine that promotes the proliferation of hepatic stellate cells and is involved in the promotion of liver fibrosis.
  • cytokines associated with hepatic injury are important for the activation of hepatic stellate cells, and the activity is further enhanced through proliferation, contraction, ECM production, site force-in production, and the like.
  • Liver fibrosis is a symptom that results from chronic liver damage caused by various causes as described above. If the symptom persists, it progresses to cirrhosis, and further progresses to liver cancer.
  • Non-patent Document 1 Ka aguchi K et al. Biochem. Biophys. Res. Commun.
  • Non-Patent Document 2 Kurihara N et al. Br J Pharmacol 2003; 139: 1085-94.
  • Therapies using these have been attempted, but at present, clinically effective prevention or No cure has been found.
  • natriuretic peptide (NP) having diuretic action is known as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).
  • NPR-A diuretic peptide receptor-A
  • NPR-B diuretic peptide receptor-B
  • ze structure As receptors for these peptides, diuretic peptide receptor-A (NPR-A), diuretic peptide receptor-B (NPR-B), etc. are known. These are membrane-bound guanylyl cycler. It is a guanylyl cyclase co-receptor with a ze structure.
  • ANP and BNP are specific ligands of NPR-A
  • CNP is a specific ligand of NPR-B
  • they increase intracellular cGMP after binding to each receptor. Therefore, it is considered to exhibit biological activities such as diuretic action and vasodilatory action.
  • Non-Patent Document 3 Rosenzweig A, and Seidman CE., Annu. Rev. Biochem., 60: 229-255, 1991. Natriuretic peptides are still reported to play an important role in controlling body fluid homeostasis and blood pressure
  • Non-Patent Document 4 OgawaY, et al., J. Clin.
  • Non-patent Document 5 Komatsu Y., et al., Endocrinology, 129: 1104-1106, 1991
  • Non-Patent Document 6 Chinkers M. and Garbers DL., A. Rev. Biochem., 60: 553-575, 1991).
  • ANP is a peptide hormone that is secreted from the heart and plays an important role in the regulation of water electrolyte metabolism and blood pressure.
  • blood ANP levels increase with the severity of cardiac hypertrophy and heart failure, and it is thought to compensate for the pathophysiology of heart failure.
  • vasodilatory and diuretic effects are manifested by ANP administration in patients with heart failure, reducing the preload and afterload of the heart, and the hemodynamic improvement effect has been confirmed (Non-patent Document 7: Suzuki T., et al.) al., Cardiovasc. Res. 51: 489-494, 2001). It is already used clinically as an acute heart failure drug.
  • BNP is a hormone found in the brain, but it is secreted mainly from the heart rather than the brain, and has a vasodilatory and diuretic action and plays an important role in regulating body fluid volume and blood pressure. Rumon.
  • the plasma BNP concentration in healthy individuals is extremely low, but increases with severity in patients with heart failure (Non-Patent Document 8: Mukoyama M., et al., J. Clin. Invest., 87: 1402-1412, 1991 )
  • BNP in blood is already high in asymptomatic heart failure and increases significantly according to the severity, so it is important as a method for evaluating heart failure function.BNP measurement is important for understanding the pathophysiology of heart failure.
  • Non-Patent Document 7 Suzuki L, et al., Cardiovasc. Res. 51: 489-494, 2001).
  • BNP is also already approved for the treatment of acute heart failure in the United States and other countries.
  • CNP is known as a bone growth factor.
  • CNP significantly promotes long bone growth
  • Non-patent Document 9 Yasoda A., et al., J. Biol. Chem). , 273: 11695-11700, 1998.
  • organ cultures of mouse fetus tibia, chondrocyte culture cells, and osteoblast cell culture cells have higher cGMP production capacity than ANP and BNP
  • Non-patent Document 10 Hagiwara H., et al., J. Biol) Chem., 269: 10729-10733, 1994
  • Non-Patent Document 11 Suda M., et al., Biochem. Biophys. Res.
  • Non-Patent Document 12 Inoue A., et al., Biochem. Biophys. Res. : 1104-1110, 1995).
  • Non-patent Document 13 Gorbig MN, Hepatology, 30: 501-509, 1999.
  • Natrium diuretic peptide has a fibrosis-inhibiting action in the heart and kidney (Non-patent document 14: Calderone A, et al. J. Clin. Invest., 101: 812-818 .; Non-patent document 15) : Suganami T. et al. 12: 2652-2663, 2001) .So far, natriuretic peptides have become a cause of liver fibrosis that causes progression to liver cirrhosis and precancerous lesions, which are the transition process to canceration.
  • Non-Patent Document 1 Ka aguchi K et al. Biochem. Biophys. Res. Commun. 2004; 315:
  • Non-Patent Document 2 urihara N et al. Br J Pharmacol 2003; 139: 1085-94. 15
  • Non-Patent Document 3 Rosenzweig A, and Seidman CE., A Awakening. Rev. Biochem.
  • Non-patent document 4 Ogawa Y, et al., J. Clin. Invest., 93: 1911-1921, 1994
  • Non-patent document 5 Komatsu Y., et al., Endocrinology, 129: 1104-1106, 1991
  • Non-patent document 6 Chinkers M. and Garbers DL., Annu. Rev. Biochem., 60: 553-575
  • Non-Patent Document 7 Suzuki T., et al., Cardiovasc. Res. 51: 489-494, 2001
  • Non-Patent Document 8 Mukoyama M., et al., J. Clin. Invest., 87: 1402-12, 1991
  • Patent Document 9 Yasoda A., et al., J. Biol. Chem., 273: 11695-11700, 1998
  • Non-patent Document 10 HagiwaraH., Et al., J. Biol. Chem., 269: 10729-10733, 1994 25
  • Non-Patent Document 1 1 Suda M., et al., Biochem. Biophys. Res. Commun., 223: 1-6, 1996
  • Non-Patent Document 12 Inoue A., et al., Biochem. Biophys. Res. Commun. 215: 1104-1110, 1995
  • Non-Patent Literature 1 3 Gorb ig M. N., Hepatology, 30: 501-509, 1999
  • Non-patent literature 14 Cal derone A, et al. J. Cl in. Invest., 101: 812-818.
  • Non-patent literature 15 Suganami T. et al. 12: 2652-2663, 2001
  • An object of the present invention is to provide a pharmaceutical composition for suppressing liver fibrosis, which is used for the prevention or treatment of cirrhosis or precancerous lesions, which contains sodium diuretic peptide as an active ingredient.
  • liver fibrosis As a method of preventing or treating liver fibrosis, (1) suppression of hepatic stellate cell activation, (2) control of site force in, which is important for liver fibrosis, ( 3) Suppression of hepatic stellate cell proliferation, (4) control of ECM degradation system, and (5) hepatocyte proliferation and hepatic stem cell transplantation. Therefore, the present inventors focused on hepatic stellate cells, which can also be called “target cells J”, particularly in the prevention or treatment of liver fibrosis, and considered that it is important to suppress the activation of hepatic stellate cells. As a result of examining the effect of the peptide on activated hepatic stellate cells in vivo, it was found that it has an inhibitory effect on liver fibrosis, and the present invention has been completed.
  • the present invention relates to the following matters.
  • a pharmaceutical composition for inhibiting liver fibrosis comprising natriuretic peptide or a pharmaceutically acceptable salt thereof as an active ingredient, and inhibiting liver fibrosis induced by activation of hepatic stellate cells.
  • natriuretic peptide is any one of atrial natriuretic peptide, brain natriuretic peptide, or C-type natriuretic peptide.
  • natriuretic peptide is any one of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.
  • natriuretic peptide is an atrial natriuretic peptide.
  • natriuretic peptide or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for inhibiting liver fibrosis.
  • natriuretic peptide is any one of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.
  • natriuretic peptide is an atrial natriuretic peptide.
  • a sodium diuretic peptide or a pharmaceutically acceptable salt thereof for suppressing liver fibrosis (10) A sodium diuretic peptide or a pharmaceutically acceptable salt thereof for suppressing liver fibrosis.
  • natriuretic peptide according to (10) above, wherein the natriuretic peptide is either atrial natriuretic peptide, brain natriuretic peptide, or C-type natriuretic peptide, or a pharmaceutically acceptable peptide thereof salt.
  • the pharmaceutical composition for inhibiting fibrosis of the liver comprising the sodium diuretic peptide according to the present invention as an active ingredient acts particularly on hepatic stellate cells to inhibit its activation, and further suppresses the progression of liver fibrosis. It plays. Suppression of liver fibrosis has increased the possibility of suppressing or treating the progression to liver cirrhosis or precancerous lesions that are transitioning to canceration.
  • composition for inhibiting liver fibrosis comprising the sodium diuretic peptide according to the present invention as an active ingredient
  • the substance exerts a special effect when acting on hepatic stellate cells to suppress its activation and suppress the progression of liver fibrosis. Suppression of liver fibrosis has made it possible to suppress or treat progression to liver cirrhosis or precancerous lesions that are the transition to canceration.
  • FIG. 1 is a graph showing the effects of ANP and CNP on serum ALT (A), serum AST (B), and serum total pyrilvin (T-bi l) (C) in DEN-induced liver fibrosis model rats. Each value on the bar graph shows the average value of 6 cases, and the graph shows the average soil standard error.
  • FIG. 2 is a graph showing the effects of ANP and CNP on serum total protein concentration (A) and serum albumin concentration (B) in DEN-induced liver fibrosis model rats. Each value on the bar graph shows the average value of 6 cases, and the graph shows the average soil standard error. : P 0.01, t test against control group (DEN).
  • Figure 3 is a photograph ( Figure 3A) showing an Azan-stained image of a liver tissue specimen of a DEN-induced liver fibrosis model and a graph ( Figure 3B) showing the area ratio (%) of cells positive by Azan staining.
  • the control group group administered with DEN only; DEN
  • ANP administration group ANP administration group
  • CNP administration group CNP administration group
  • CNP each showing a typical example.
  • the ANP administration group (ANP) or the CNP administration group (CNP) has fewer collagen fiber regions stained blue than the control group (DEN).
  • Fig. 3B also shows that Azan staining-positive cells are significantly reduced in both the ANP administration group (ANP) and the CNP administration group (CNP) compared to the control group (DEN) ( «: p ⁇ 0. 01) o
  • Fig. 4 is a photograph (Fig. 4A) showing a Sirius Red stained image of a liver tissue specimen of a DEN-induced liver fibrosis model and a graph (Fig. 4B) showing the area ratio (%) of cells positive by Sirius Red staining. is there.
  • a typical example is shown for each of the control group (DEN), ANP administration group (ANP), and CNP administration group (CNP).
  • the collagen fiber region stained in reddish brown is less in the ANP administration group (ANP) or CNP administration group (CNP) than in the control group (DEN).
  • FIG. 4B both the ANP administration group (ANP) and the CNP administration group (CNP) compared to the control group (DEN). Showed a significant decrease in staining-positive cells ( ⁇ : p ⁇ 0. 01).
  • Fig. 5 is a photograph (Fig. 5 ⁇ ) showing an a SMA antibody-stained image of a liver tissue specimen of a DE-induced liver fibrosis model and a graph (Fig. 5B) showing the area ratio (%) of cells positive by a SMA staining.
  • a control group (DEN;), an ANP administration group (ANP), and a CNP administration group (CNP) are shown as typical examples.
  • the smooth muscle region stained brown is less in the ANP administration group (ANP) or CNP administration group (CNP) than in the control group (DEN).
  • FIG. 5B it was shown that anti-SMA antibody staining positive cells were significantly decreased in both the ANP administration group (ANP) and the CNP administration group (CNP) compared to the control group (DEN) ( ⁇ : P ⁇ 0. 01).
  • Figure 6 shows the type 1 procollagen (collagen I) gene (A), MMP2 gene (B), T IMP-1 gene (C), and TIMP-2 gene (D) in the liver of the DEN-induced liver fibrosis model ) It is a graph showing the expression. Each value represents the average soil standard error of 6 cases. : P ⁇ 0. 01, t test against control group (DEN).
  • Figure 7 shows that hepatic stellate cells isolated from rats (Figure 7A) or HSC-T6 cells (established cell lines of rat hepatic stellate cells) ( Figure 7B). It is a figure which shows the result of a Western plot which shows suppressing protein expression level.
  • Drosophila fibrosis is a response to hepatocyte necrosis and damage, and refers to changes in liver tissue that occur in complex ways involving many factors.
  • Liver fibrosis is caused by, for example, liver inflammation or damage caused by poisons, changes in liver blood flow, or infections caused by liver viruses or bacteria, various storage abnormalities in hepatocytes, or chemicals or drugs such as alcohol or methotrexate. And circulatory disturbance to the liver such as chronic heart failure.
  • Hepatic stellate cells are stimulated by excessive production and accumulation of ECM due to cytokines such as TGF-j3 produced during liver damage and inflammation, and endotoxemia caused by high intake of alcohol. This causes a pathology of liver fibrosis.
  • cytokines such as TGF-j3 produced during liver damage and inflammation, and endotoxemia caused by high intake of alcohol. This causes a pathology of liver fibrosis.
  • hepatic stellate cells produce matrix-degrading enzyme (MMP) and its inhibitory factor (TIMP), site force-in such as TGF-3, PDGF, and growth factors such as HGF, and hepatic fibrosis.
  • natriuretic peptide is administered to animals.
  • MMP type I collagen gene opioid matrix degrading enzyme
  • TRIP type I collagen gene opioid matrix degrading enzyme suppressor
  • the substance that can be used as the active ingredient of the pharmaceutical composition according to the present invention may be any substance that has the property of enhancing cGMP production via NPR-A, which is a sodium diuretic peptide (NP) receptor.
  • NPR-A sodium diuretic peptide
  • NP sodium diuretic peptide
  • Natriuretic peptides which are peptidic substances, are preferred, and examples of natriuretic peptides include atrial natriuretic peptide (ANP), brain sodium diuretic peptide (BNP), and C-type natriuretic peptide (CNP). It is
  • ANP in the present invention a human-derived ANP (SLRRSSCFGG RMDRIGAQSG LGCNSFRY: SEQ ID NO: 1) consisting of 28 amino acids, a rat-derived ANP (SLRRSSCFGG RIDRIGAQSG LGCNSFRY: SEQ ID NO: 3), natriuretic peptide (NP) Those having a property capable of enhancing cGMP production via the receptor NPR-A can be used.
  • these peptides which are active ingredients according to the present invention, exhibit a property capable of enhancing cGMP production via NPR-A, which is a natriuretic peptide (NP) receptor, at least the ring structure of the MP (for example, In the case of the amino acid sequence of human ANP, a peptide having a ring structure based on the formation of a disulfide bond based on 7-position Cys and 23-position Cys of SEQ ID NO: 1 and a C-terminal portion following the ring structure (that is, In the case of human ANP, SEQ ID NO: 2) corresponding to positions 7-28 of SEQ ID NO: 1 may be used.
  • NPR-A which is a natriuretic peptide (NP) receptor
  • NP natriuretic peptide
  • Examples of the peptide having such a structural feature include the ANP itself described in SEQ ID N0: 1, or a peptide having a partial amino acid sequence thereof, from amino acids at positions 7 to 28 of the human ANP.
  • a peptide (SEQ ID NO: 2) consisting of amino acids 7-28 of the above human ANP itself may be mentioned.
  • human-derived MP consisting of 32 amino acids (SPKMVQGSGC FGRKMDRISS SSGLGCKVLR RH: SEQ ID NO: 4), buyu-derived BNP (SPKTMRDSGC FGRRLDRIGS LSGLGCNVLR RY: SEQ ID NO: 6), rat-derived MP ( SQDSAFRIQE RLRNSKMAHS SSCFGQKIDR Those having the property of enhancing cGMP production via NPR-A, a natriuretic peptide (NP) receptor, such as IGAVSRLGCD GLRLF: SEQ ID NO: 7), can be used.
  • NP natriuretic peptide
  • a natriuretic peptide (NP) receptor at least the ring structure of the BNP (for example, human)
  • NP natriuretic peptide
  • a peptide having a ring structure based on the formation of a disulfide bond based on Cys 10 and 26 of SEQ ID NO: 4 and a C-terminal part following the ring structure ie In the case of human BNP, SEQ ID NO: 5
  • SEQ ID NO: 5 a C-terminal part following the ring structure
  • Peptides having such structural characteristics include, for example, the BNP itself described in SEQ ID N0: 4, or a peptide having a partial amino acid sequence thereof, from the amino acids at positions 10 to 32 of the above-mentioned BNP.
  • a peptide encapsulating the peptide for example, a peptide (SEQ ID NO: 5) itself consisting of amino acids at positions 10 to 32 of the above human BNP can be mentioned.
  • CNP human-derived CNP consisting of 22 amino acids (GLSKGCFGLK LDRIGSMSGL GC: SEQ ID NO: 8, BUTATA and rat also have the same amino acid sequence), birch-derived CNP (GLSRSCFGVK LDRIGSMSGL GC: SEQ ID NO: 10), CNP (GYSRGCFGVK LDRIGAFSGL GC: SEQ ID NO: 11), etc. that have the property of enhancing cGMP production through NPR-A, a natriuretic peptide (NP) receptor be able to.
  • NP natriuretic peptide
  • these peptides as active ingredients according to the present invention exhibit the property of enhancing cGMP production via NPR-A which is a natriuretic peptide (NP) receptor, at least the ring structure of the CNP (for example, In the case of the amino acid sequence of human CNP, a peptide having a ring structure based on the formation of a disulfide bond based on 6-position Cys and 22-position Cys of SEQ ID N0: 8 (ie, SEQ ID NO: 9) That's fine.
  • the peptide having such a structural feature include the CNP itself described in SEQ ID N0: 4, or a peptide having a partial amino acid sequence thereof and consisting of amino acids at positions 6-22 of the human CNP.
  • the peptide encapsulating the peptide such as the peptide consisting of amino acids at positions 6-22 of the human CNP (SEQ ID NO: 9) itself.
  • the natriuretic peptide according to the present invention includes a purely isolated and purified natural product.
  • the amino acid residue in the sequence can be obtained by modification such as deletion, substitution, addition, insertion, etc., and the substance obtained by any method acts on NP receptor NPR-A Any substance that can enhance cGMP production can be used.
  • the obtained substance can act on NP receptor NPR-A and enhance cGMP production can be easily measured by a person skilled in the art by a conventional method. Specifically, the substance can be added to cultured cells in which PR-A (Chinkers M et al. Nature 338; 78-83, 1989) is forcibly expressed, and cGMP production ability can be evaluated.
  • PR-A Chokers M et al. Nature 338; 78-83, 1989
  • the substance that can be used as an active ingredient of the pharmaceutical composition according to the present invention is a pharmaceutically acceptable substance having a property capable of enhancing cGMP production via NPR-A, which is the above-mentioned sodium diuretic peptide (NP) receptor.
  • NP sodium diuretic peptide
  • a pharmaceutically acceptable salt of sodium diuretic peptide that is, in the present invention, an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, or an organic acid such as formic acid, acetic acid, butyric acid, succinic acid, and succinic acid is added as an active ingredient.
  • metal salts such as sodium, potassium, lithium and calcium, and salts with organic bases of the above-mentioned substances can be used as active ingredients.
  • the pharmaceutical composition according to the present invention may be a free form of the substance relating to the active ingredient or a pharmaceutically acceptable salt thereof.
  • composition of the present invention significantly reduces the expression of type I collagen gene and matrix degrading enzyme (MMP) suppressor (TIMP) gene by hepatic stellate cells, and It can suppress liver fibrosis induced by activation.
  • MMP matrix degrading enzyme
  • the above-described composition of the present invention is administered to prevent or treat liver cirrhosis or precancerous disease caused by liver fibrosis by suppressing liver fibrosis as described above. You can also.
  • Substances that can be used as active ingredients of the pharmaceutical composition according to the present invention or pharmacologically acceptable substances thereof are mixed with known pharmacologically acceptable carriers, excipients, diluents and the like, and are generally used in medicines, that is, oral administration methods, or intravenous administration, muscle It is preferably administered by a parenteral administration method such as internal administration or subcutaneous administration.
  • the active ingredient when it is a peptidic substance, it can be orally administered as a preparation that is not easily degraded in the digestive tract, for example, as a microcapsule encapsulating the active ingredient peptide in a ribosome.
  • it can be administered by absorption through the mucosa other than the digestive tract, such as the rectum, intranasal, sublingually. In this case, it can be administered in the form of suppositories, nasal sprays, sublingual tablets.
  • the dose of a substance that can be used as an active ingredient of the pharmaceutical composition according to the present invention is generally 0.1 xg per day, although it varies depending on the type of disease, patient age, weight, symptom severity, and administration route. / kg to 100 ig / kg can be administered, preferably 0.5 g / kg to 5 mg / kg.
  • the frequency of administration of the pharmaceutical composition according to the present invention will vary depending on the active ingredient used, the route of administration, and the particular disease being treated. For example, when sodium diuretic peptide is administered orally, it is preferable to prescribe it at a frequency of not more than 4 times per day, and when administered intravenously, it can be administered continuously using an infusion pump. preferable.
  • DEN N-jethyl nitrosamine
  • a persistent liver injury model was prepared by intraperitoneally administering DEN (Wako Pure Chemicals; 200 mg / kg) twice a week for 4 weeks to Wistar male rats (Japan SLC).
  • DEN Pure Chemicals
  • human MP ASBIPHOMA Co., Ltd.
  • human CNP ASBIPHOMA Co., Ltd.
  • Continuous intravenous administration was performed as follows. That is, the animals were anesthetized with pentobarbital sodium and then kept in the supine position. A midline cervical incision was made, and a Hyde-Coat catheter (AccessTechnology, catalog number: CNC-3H) was inserted into the jugular vein. The catheter was guided subcutaneously through the back of the neck through the back of the neck and connected to an infusion pump (US Medellell, Inc., trade name: Infu-Disk, catalog number: 05-0030-S) fixed to the back to administer the drug. In the control group, no drug was administered.
  • ALT alanin aminotransferase
  • GPT glutamate pyruvate transaminase
  • aspartate aminotransferase AST also called GOT (Daltamate Oxaloacetate Transaminase)
  • serum ALT, AST, and total pyrilrubin concentrations were all compared to the control group.
  • Figures 1A-C serum total protein concentration and serum albumin concentration, which are indicators of liver function, were measured. Serum total protein concentration and serum albumin concentration were higher in both treatment groups than in the control group. Maintained ( Figures 2A-B). From these data, it was shown that the decrease in monthly function due to DEN was suppressed in the ANP administration group and the CNP administration group.
  • -a-smooth muscle actin ( ⁇ -SMA) is known as an indicator of hepatic stellate cell activation, and as an antibody against ⁇ -smooth muscle actin, anti-aSMA monoclonal antibody (Dako Apan) was used.
  • type 1 procollagen which is an index of liver fibrosis, matrix metalloptidase-2 (Mtrix-2), matrix metallopeptidase_13 (matrix metallopeptidase-13; MMP-13), tissue metabolite MRNA of each gene of oral protease inhibitor-1 (tissue inhibitor of metalloproteinase-1; TIMP-1) and tissue metaprotease inhibitor-2 (Tissue inhibitor of metalloproteinase-2; TIMP-2) Expression in the liver was evaluated by real-time PCR according to a conventional method (Kawaguchi K. et al., Biochem. Biophys. Res. Com., 2004; 315: 187-95).
  • RNA from rat liver was isolated using RNeasy-kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.
  • the internal standard was / 3_actin.
  • Taqman reverse transcriptase reagent (Roche Diagnostics, Indianapolis, IN, USA) was used for synthesis of cDNA as described in the manufacturer's instructions.
  • -Actin was used as an internal control to perform specific quantification of gene expression as described in the manual.
  • a method based on the threshold cycle number and standard curve was used to calculate the relative amount of target RNA.
  • Antisense 5 '-caataggaccagaaggaccagca-3' (SEQ ID N0: 13)
  • Antisense 5'-gtcactgtccgccaaataaacc-3 '(SEQ ID NO: 15)
  • Antisense 5'-cgctgcggttctgggacttgtg-3 '(SEQ ID NO: 17)
  • Antisense 5'-tcttgccatctccttccgccttcc_3 '(SEQ ID NO: 19).
  • the insert was confirmed by DNA sequencing and used as a probe for real-time PCR analysis.
  • Hepatic stellate cells were isolated from the liver of Wistar male rats (Nihon SLS1) by conventional methods (Ka aguchi K., et al., Biochem. Biophys. Res. Commun., 2004; 315: 187-95) did. Specifically, rat liver was maintained at 37 ° C with Ca2 + and Mg2 + free Krebs-Ringer solution, 0.1% pronase E (Merck, Germany), 0.032% collagenase (sum)
  • hepatic stellate cell fraction contained in the upper white layer after centrifugation was collected and centrifuged at 450 g for 8 minutes to collect cells.
  • Dulbecco's modified Eagle's medium (Nissui Pharmaceutical, Tokyo, Japan) containing 10% urine fetal serum (Co ⁇ onwealth Serum Laboratories, Australia), lOOU / mL penicillin, lOOU / mL streptomycin (Gibco Laboratories, Life Technologies, USA) )
  • the expression level of 25 tin was measured by the Western plot method.
  • Western plotting was performed using an anti-aSMA monoclonal antibody (Dako Japan) and a western rabbit sapiperoxidase-conjugated anti-mouse IgG secondary antibody (Amersham). It was.
  • Figure 7 shows the results after 24 hours of addition of sputum to the culture medium of isolated primary hepatic stellate cells or HSC-T6 cells ( Figures 7 and 7 respectively).
  • ⁇ suppressed the protein expression level of a-SMA in a concentration-dependent manner.
  • CNP indicating that sputum and CNP have the effect of suppressing hepatic stellate cell activation.
  • sputum and CNP act on hepatic stellate cells to suppress liver fibrosis and maintain liver function, and these effects may involve inhibition of hepatic stellate cell activation. found.
  • the pharmaceutical composition for inhibiting liver fibrosis comprising the sodium diuretic peptide according to the present invention as an active ingredient has a special effect of acting on hepatic stellate cells to suppress its activity and suppress the progression of liver fibrosis. It plays. Suppression of liver fibrosis has made it possible to suppress or treat progression to liver cirrhosis or precancerous lesions that are the transition to canceration.

Abstract

La présente invention concerne une composition pharmaceutique destinée à la prévention d'une fibrose hépatique, qui comprend un peptide natriurétique en tant que principe actif et peut être utilisée pour la prévention ou le traitement d'une cirrhose ou d'une lésion précancéreuse. L'attention est particulièrement concentrée sur une cellule étoilée du foie qui l'on croit est une « cellule cible » pour la prévention ou le traitement d'une fibrose hépatique, et il est considéré que la prévention de l'activation d'une cellule étoilée du foie est importante pour la prévention ou le traitement d'une fibrose hépatique. Ensuite, il a été réalisé une étude quant à l'effet d'un peptide natriurétique sur une cellule étoilée du foie activée in vivo, et il a été découvert qu'un peptide natriurétique a un effet inhibiteur sur une fibrose hépatique.
PCT/JP2008/058322 2007-04-24 2008-04-24 Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif WO2008133349A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-114293 2007-04-24
JP2007114293A JP2010168283A (ja) 2007-04-24 2007-04-24 ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤

Publications (1)

Publication Number Publication Date
WO2008133349A1 true WO2008133349A1 (fr) 2008-11-06

Family

ID=39925788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058322 WO2008133349A1 (fr) 2007-04-24 2008-04-24 Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif

Country Status (2)

Country Link
JP (1) JP2010168283A (fr)
WO (1) WO2008133349A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358270B2 (en) 2009-08-27 2016-06-07 Igisu Co., Ltd. Method of treating rhinitis with B-type and C-type natriuretic peptides
US9358269B2 (en) 2009-07-23 2016-06-07 Igisu Co., Ltd Method for treating dermatitis and improving skin texture using natriuretic peptides

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110801514A (zh) 2011-01-21 2020-02-18 Igisu株式会社 秃头症治疗剂
CN103402542B (zh) * 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
JP6038795B2 (ja) * 2011-08-19 2016-12-07 国立研究開発法人国立循環器病研究センター ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABELL T.J. ET AL.: "Atrial Natriuretic Factor Inhibits Proliferation of Vascular Smooth Muscle Cells Stimulated by Platelet-Derived Growth Factor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 160, no. 3, 1989, pages 1392 - 1396 *
GORBIG M.N. ET AL.: "Atrial Natriuretic Peptide Antagonize Endothelin-Induced Calcium Increase and Cell Contraction in Cultured Human Hepatic Stellate Cells", HEPATOLOGY, vol. 30, no. 2, 1999, pages 501 - 509 *
KOHNO M. ET AL.: "Interaction of PDGF and natriuretic peptides on mesangial cell proliferation and endothelin secretion", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 265, 1993, pages E673 - E679 *
TAO J. ET AL.: "Biological Effects of C-type Natriuretic Peptide in Human Myofibroblastic Hepatic Stellate Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 34, 1999, pages 23761 - 23769, XP055184845, DOI: doi:10.1074/jbc.274.34.23761 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358269B2 (en) 2009-07-23 2016-06-07 Igisu Co., Ltd Method for treating dermatitis and improving skin texture using natriuretic peptides
US9968654B2 (en) 2009-07-23 2018-05-15 Igisu Co., Ltd. Method of treatment dermatitis with c-type natriuretic peptide derivatives
US10946072B2 (en) 2009-07-23 2021-03-16 Igisu Co., Ltd. Method for treating dermatitis and improving skin texture using B-type natriuretic peptides
US9358270B2 (en) 2009-08-27 2016-06-07 Igisu Co., Ltd. Method of treating rhinitis with B-type and C-type natriuretic peptides
US9962429B2 (en) 2009-08-27 2018-05-08 Igisu Co., Ltd. Method for treating rhinitis with B and C-type natriuretic peptide containing chimeric ring structures
US11452762B2 (en) 2009-08-27 2022-09-27 Igisu Co., Ltd. Method of treating rhinitis with C-type natriuretic peptides

Also Published As

Publication number Publication date
JP2010168283A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
US6599876B2 (en) Medicament and method for treating renal disease
Needleman et al. The biochemical pharmacology of atrial peptides
Shankland et al. Expression of transforming growth factor-β1 during diabetic renal hypertrophy
Davidson et al. Brain natriuretic peptide
WO2006115274A1 (fr) Inducteur de differenciation des progeniteurs myeloerythroides
WO2006056885A2 (fr) Nouveaux peptides igf-i
WO2008133349A1 (fr) Agent destiné à la prévention d'une cirrhose/d'une lésion précancéreuse comprenant un peptide natriurétique en tant que principe actif
Humphreys et al. Cardiovascular effects of melanocortins
KR20190122212A (ko) 심근증, 진구성 심근경색 및 만성심부전의 치료약
Biolo et al. Pentoxifylline acutely reduces protein catabolism in chronically uremic patients
US20040229784A1 (en) Cancer Treatment Using proANP Peptides
Burrell et al. Vasopressin receptor antagonism—a therapeutic option in heart failure and hypertension
WO2003006025A1 (fr) Procedes et materiaux pour traiter des etats osseux
Zheng et al. Relaxin ameliorates renal fibrosis and expression of endothelial cell transition markers in rats of isoproterenol-induced heart failure
Konturek et al. Expression of transforming growth factor-beta1 and epidermal growth factor in caerulein-induced pancreatitis in rat
Vemulapalli et al. Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats
WO2000023100A9 (fr) Genes et proteines destines a la prevention et therapie de maladies renales et de troubles associes
JP5207316B2 (ja) 腹膜線維化抑制用医薬組成物
JP2005534677A (ja) Ｉｉ型糖尿病を治療又は予防するためのインターロイキン１受容体アンタゴニスト及び／又はピロリジンジチオカルバメートの使用
JP2011207867A (ja) 腹膜癒着防止用医薬組成物
AU2009294362A1 (en) Use of CTGF as a cardioprotectant
Jiang et al. Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats
Mazzocchi et al. Adrenomedullin (AM) and AM receptor type 2 expression is up-regulated in prostate carcinomas (PC), and AM stimulates in vitro growth of a PC-derived cell line by enhancing proliferation and decreasing apoptosis rates
KR101780597B1 (ko) TIF1γ의 발현 또는 활성 증강제를 유효성분으로 포함하는 간 섬유화 또는 간경화 예방 또는 치료용 조성물
Wegner et al. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740987

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740987

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP